Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. The deal will see Superluminal use its GPCR platform ...

Eli Lilly and Co (NYSE:LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other ...

Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal's lead candidate not part of deal with Lilly Aug 14 (Reuters) - Eli ...

(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 billion, granting Lilly access to its AI-driven platform to discover and develop ...

Eli Lilly and Company (NYSE:LLY) is one of the 9 Best NYSE Stocks to Buy According to Hedge Funds. On August 14, Reuters reported that Eli Lilly and Company (NYSE:LLY) has entered into a deal worth $1 ...

Eli Lilly and Co. is collaborating with Boston-based Superluminal Medicines to use artificial intelligence to discover small-molecule drugs for cardiometabolic disease and obesity in an agreement ...

Superluminal Medicines, a healthcare company integrating AI/ML, announced partnership with Eli Lilly (NYSE:LLY) to advance small molecule therapeutics targeting cardiometabolic diseases and obesity.

(Reuters) -Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic ...